A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Recruiting

Phase 2

AlirocumabA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07477704

Conditions

Hypercholesterolemia

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Alirocumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-27. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-06-10.